Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
NCT ID: NCT00520286
Last Updated: 2017-04-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
210 participants
INTERVENTIONAL
2007-12-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
NCT00469508
A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence
NCT00538655
Safety and Tolerability of Modafinil for Methamphetamine Dependence
NCT00569374
A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
NCT01354470
Effects of Modafinil in Methamphetamine Dependence
NCT00751023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Modafinil
Participants will receive a Modafinil 200 mg or 400 mg tablet one time per day for 12 weeks
Modafinil
200 mg or 400 mg /daily
Placebo
Participants will receive a matching Modafinil placebo 200 mg or 400 mg tablet one time per day for 12 weeks
Placebo
Placebo / daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modafinil
200 mg or 400 mg /daily
Placebo
Placebo / daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Methamphetamine dependent as defined by DSM-IV criteria
* Must be in good general heath with a history of methamphetamine use at screening
* Must be able to provide written informed consent
* If female and of child bearing potential, must agree to use birth control.
Exclusion Criteria
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Elkashef, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute on Drug Abuse (NIDA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South Bay Treatment Center
San Diego, California, United States
Matrix Institute on Addictions
Tarzana, California, United States
Torrance Site
Torrance, California, United States
University of Colorado Health Sciences Center
Denver, Colorado, United States
John A. Burns School of Medicine
Honolulu, Hawaii, United States
Powell Chemical Dependency Center
Des Moines, Iowa, United States
START Research and Treatment
Kansas City, Missouri, United States
Salt Lake City VA Medical Center
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, Kahn R, Chiang N, Beresford T, Campbell J, Haning W, Mawhinney J, McCann M, Rawson R, Stock C, Weis D, Yu E, Elkashef AM. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012 Jan 1;120(1-3):135-41. doi: 10.1016/j.drugalcdep.2011.07.007. Epub 2011 Aug 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-CSP-1026-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.